Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The legal team said the jury's decision could make medics think twice before allowing the injured to return to the field.
Read Full NewsPhase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.
FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis
Renal Transplantation May Lower Sleep Disorder Risk Versus Dialysis
BMI, Inflammatory Bowel Disease Both Show Causal Effect on HS Development
The HCPFive: Top News for Healthcare Providers from the Week of 12/14
1.
According to a study, white Americans are overdiagnosing melanoma at an alarming rate.
2.
Clinical trial could lead to new 'gold standard' test for prostate cancer detection
3.
A Possible Novel CAR-T Treatment for High-Risk R/R Follicular Lymphoma May Be Liso-Cel.
4.
Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.
5.
Prostate cancer screening seems to be improved by PSA, biomarker testing, and MRI combined.
1.
The Mysterious World of Petechiae: Exploring Causes and Treatments
2.
An Introduction To The CA 15-3 Tumor Marker Test For Cancer Patients
3.
Everything You Need To Know About Splenic Infarction – Symptoms, Treatments, And Prevention
4.
AI Revolutionizes Immunotherapy: Unveiling Biomarkers with Machine Intelligence
5.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
2.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
3.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
4.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
5.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge